Article
Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study.
BMJ open - 4 Jan 2022
Watanabe Kageaki, Yoh Kiyotaka, Hosomi Yukio, Usui Kazuhiro, Naka Go, Kishi Kazuma, Uemura Kohei, Ohashi Yasuo, Kunitoh Hideo
Abstract excerpt
INTRODUCTION: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is widely used as the first-line treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC). Nevertheless, most cases ultimately acquire resistance to osimertinib, and no effective treatment has been currently established for cases having progressive disease (PD) with osimertinib. In...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.